#USA #Menlo Park #GRAIL #Galleri Test #PATHFINDER 2

Enhancing Cancer Detection: Insights from GRAIL's PATHFINDER 2 Study

In a groundbreaking announcement at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO), GRAIL, Inc., a leading healthcare firm, showcased its latest findings from the PATHFINDER 2 study, which assessed the efficacy of the Galleri® multi-cancer early detection (MCED) test. With a participant base exceeding 35,000 individuals, this research illustrated a transformative leap in cancer detection strategies, particularly for those at elevated risk of developing cancer.

The PATHFINDER 2 study, the largest of its kind in North America, aimed to evaluate the safety and performance of the Galleri test when integrated with standard cancer screenings. Participants included adults aged 50 and above who exhibited no symptoms or clinical indications of cancer, marking a significant step in preventive healthcare practices.

Groundbreaking Statistics

The results were nothing short of remarkable. When Galleri was added to traditional screenings for breast, colorectal, cervical, and lung cancers, the overall cancer detection rate surged by 6.5-fold. This increase is critical as only 14% of all cancers in the U.S. are typically identified through guideline-recommended screenings. Notably, 71% of the cancers detected using the Galleri test were found at stages I and II, indicating that the test is particularly effective at identifying cancers early when they are most treatable.

Dr. Josh Ofman, President and CEO-Elect of GRAIL, highlighted the significance of these findings, stating, "Early detection is pivotal in improving cancer outcomes, increasing treatment options, and enhancing the potential for a cure." The data contributed significantly to the growing body of clinical evidence supporting the Galleri test as a vital tool in early cancer detection strategies.

Patient Impact

The Galleri test not only detected cancers earlier but did so with a high degree of accuracy. For instance, out of the nearly 300 participants who tested positive for cancer signals, 173 were confirmed to have cancer, yielding a positive predictive value (PPV) of 60.3%. Such figures underscore the reliability of the Galleri test in identifying malignancies, potentially changing the landscape of cancer screenings.

Moreover, the test demonstrated impressive sensitivity rates of 69.8%, particularly for the twelve types of cancers that account for a significant number of deaths in the U.S. Specificity was also exceptionally high at 99.6%, indicating that the test produces a low false positive rate, thus minimizing unnecessary anxiety and invasive follow-up procedures for patients.

Advantages of Galleri

One of the standout features of the Galleri test is its ability to identify not only the presence of cancer but also predict the Cancer Signal Origin (CSO) with 91.3% accuracy. This precision aids in streamlining diagnostic processes, reducing the median time taken for diagnostic resolution to 48 days. Importantly, only a small percentage (0.6%) of participants underwent invasive procedures after receiving a positive MCED result, illustrating the safety of this innovative testing method.

Conclusion

The PATHFINDER 2 study represents a pivotal development in the fight against cancer, promoting earlier and more effective detection methods. As a complement to existing screening protocols, the Galleri test has illustrated its potential to revolutionize how healthcare providers approach cancer diagnosis, ultimately saving lives through timely and accurate identification of cancers.

With applications spanning a range of cancer types, including those currently lacking standard screening options, Galleri stands poised to become an indispensable tool in early cancer detection strategies. GRAIL continues to lead the charge in the early detection of cancer by harnessing the power of advanced technology and robust clinical research.

For further inquiries and updates on the Galleri test, visit GRAIL's official website at grail.com.